FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3195650180> ?p ?o ?g. }

• W3195650180 endingPage "11989" @default.
• W3195650180 startingPage "11972" @default.
• W3195650180 abstract "The three pan-genotypic HCV NS3/4A protease inhibitors (PIs) currently in clinical use-grazoprevir, glecaprevir, and voxilaprevir-are quinoxaline-based P2-P4 macrocycles and thus exhibit similar resistance profiles. Using our quinoxaline-based P1-P3 macrocyclic lead compounds as an alternative chemical scaffold, we explored structure-activity relationships (SARs) at the P2 and P4 positions to develop pan-genotypic PIs that avoid drug resistance. A structure-guided strategy was used to design and synthesize two series of compounds with different P2 quinoxalines in combination with diverse P4 groups of varying sizes and shapes, with and without fluorine substitutions. Our SAR data and cocrystal structures revealed the interplay between the P2 and P4 groups, which influenced inhibitor binding and the overall resistance profile. Optimizing inhibitor interactions in the S4 pocket led to PIs with excellent antiviral activity against clinically relevant PI-resistant HCV variants and genotype 3, providing potential pan-genotypic inhibitors with improved resistance profiles." @default.
• W3195650180 created "2021-08-30" @default.
• W3195650180 creator A5009290437 @default.
• W3195650180 creator A5018298529 @default.
• W3195650180 creator A5019115288 @default.
• W3195650180 creator A5022630086 @default.
• W3195650180 creator A5025380592 @default.
• W3195650180 creator A5035079399 @default.
• W3195650180 creator A5035786517 @default.
• W3195650180 creator A5037959629 @default.
• W3195650180 creator A5042931433 @default.
• W3195650180 creator A5051512607 @default.
• W3195650180 creator A5061785075 @default.
• W3195650180 creator A5062090637 @default.
• W3195650180 creator A5062822027 @default.
• W3195650180 creator A5065580202 @default.
• W3195650180 date "2021-08-18" @default.
• W3195650180 modified "2023-10-15" @default.
• W3195650180 title "Discovery of Quinoxaline-Based P1–P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants" @default.
• W3195650180 cites W1539796472 @default.
• W3195650180 cites W1968261613 @default.
• W3195650180 cites W1978180809 @default.
• W3195650180 cites W1987873124 @default.
• W3195650180 cites W1995753428 @default.
• W3195650180 cites W1996607909 @default.
• W3195650180 cites W2001138984 @default.
• W3195650180 cites W2014509089 @default.
• W3195650180 cites W2023563124 @default.
• W3195650180 cites W2042063943 @default.
• W3195650180 cites W2087614030 @default.
• W3195650180 cites W2112024536 @default.
• W3195650180 cites W2119571917 @default.
• W3195650180 cites W2121119506 @default.
• W3195650180 cites W2122339645 @default.
• W3195650180 cites W2130921346 @default.
• W3195650180 cites W2133036275 @default.
• W3195650180 cites W2134201060 @default.
• W3195650180 cites W2141361007 @default.
• W3195650180 cites W2144081223 @default.
• W3195650180 cites W2150463882 @default.
• W3195650180 cites W2180229411 @default.
• W3195650180 cites W2208621220 @default.
• W3195650180 cites W2264719596 @default.
• W3195650180 cites W2318156787 @default.
• W3195650180 cites W2511087017 @default.
• W3195650180 cites W2511243621 @default.
• W3195650180 cites W2512236949 @default.
• W3195650180 cites W2623185018 @default.
• W3195650180 cites W2765116944 @default.
• W3195650180 cites W2765212316 @default.
• W3195650180 cites W2769985632 @default.
• W3195650180 cites W2785609333 @default.
• W3195650180 cites W2886776749 @default.
• W3195650180 cites W2888428304 @default.
• W3195650180 cites W2920319972 @default.
• W3195650180 cites W2925231761 @default.
• W3195650180 cites W2939518231 @default.
• W3195650180 cites W2976752549 @default.
• W3195650180 cites W2998383951 @default.
• W3195650180 cites W3014308339 @default.
• W3195650180 cites W3047835683 @default.
• W3195650180 cites W3088020815 @default.
• W3195650180 cites W3106785795 @default.
• W3195650180 cites W3110060352 @default.
• W3195650180 cites W3118294308 @default.
• W3195650180 cites W3136569106 @default.
• W3195650180 cites W83140495 @default.
• W3195650180 doi "https://doi.org/10.1021/acs.jmedchem.1c00554" @default.
• W3195650180 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34405680" @default.
• W3195650180 hasPublicationYear "2021" @default.
• W3195650180 type Work @default.
• W3195650180 sameAs 3195650180 @default.
• W3195650180 citedByCount "12" @default.
• W3195650180 countsByYear W31956501802021 @default.
• W3195650180 countsByYear W31956501802022 @default.
• W3195650180 countsByYear W31956501802023 @default.
• W3195650180 crossrefType "journal-article" @default.
• W3195650180 hasAuthorship W3195650180A5009290437 @default.
• W3195650180 hasAuthorship W3195650180A5018298529 @default.
• W3195650180 hasAuthorship W3195650180A5019115288 @default.
• W3195650180 hasAuthorship W3195650180A5022630086 @default.
• W3195650180 hasAuthorship W3195650180A5025380592 @default.
• W3195650180 hasAuthorship W3195650180A5035079399 @default.
• W3195650180 hasAuthorship W3195650180A5035786517 @default.
• W3195650180 hasAuthorship W3195650180A5037959629 @default.
• W3195650180 hasAuthorship W3195650180A5042931433 @default.
• W3195650180 hasAuthorship W3195650180A5051512607 @default.
• W3195650180 hasAuthorship W3195650180A5061785075 @default.
• W3195650180 hasAuthorship W3195650180A5062090637 @default.
• W3195650180 hasAuthorship W3195650180A5062822027 @default.
• W3195650180 hasAuthorship W3195650180A5065580202 @default.
• W3195650180 hasBestOaLocation W31956501802 @default.
• W3195650180 hasConcept C104317684 @default.
• W3195650180 hasConcept C114851261 @default.
• W3195650180 hasConcept C132379496 @default.
• W3195650180 hasConcept C135763542 @default.
• W3195650180 hasConcept C142462285 @default.
• W3195650180 hasConcept C159047783 @default.

• next